|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
June 2007FeaturesCover Story Oral Oncologics Join the War on CancerThe new "smart pills" attack tumors before they can grow and spread, giving hope to cancer patients that they can live longer, more productive lives. Payers are hesitant to make a leap of faith until longitudinal data on clinical outcomes
and cost offsets persuade them of the value of the oral therapies. Clinical Taking Control of ComplianceThe cost of biologic therapies adds urgency to the need to develop realistic compliance strategies. By engaging and educating both the physician and patient, some MCOs are working hard to address at what has always been a complicated and formidable issue. Business Biotechnology in India: Just What the Doctor Outsourced?Always looking for a way to do things faster, cheaper, and with a lower potential for risk, biotech is turning its attention toward India, where opportunities are plentiful for research and development, manufacturing, and clinical trials. Economics The Arrival of Average Sales PriceHealth plans are beginning to adopt the average sales price method of paying oncologists and other specialists for office-administered drugs. ASP is more transparent and has a smaller markup than its much maligned predecessor, average wholesale price. The speed of ASP uptake will affect everyone who makes, sells, prescribes, and takes these medications. Leading Edge The World of Stem Cell Therapy: Anonymity is Not an OptionAlthough it remains poised to become one of the biggest biotech markets, stem cell therapy continues to operate under a microscope. Investigators have a lot of explaining to do — both to the public and private payers — why it makes sense to cover their treatments. DepartmentsOpeners In Search of a Better Way
Michael D. Dalzell Editorial Phone Home
David B. Nash, MD, MBA Washington Watch PDUFA Faces Rough Reauthorization
John Carroll Diagnostics and Devices 'Natural Plastics' Ripe With Potential
Bob Carlson, MHA Drug Track Approvals, FDA Actions, Clinical Trials
Bob Carlson, MHA Biotech Business Debate on Follow-on Biologics Intensifies After Release of Report
Amanda Brower Trends Commercial Formularies Face Pressure To Go 4-Tier
Lola Butcher |
|||||